Press release

TxCell appoints Biogen's Dr. Olivier Danos, pioneer in gene therapy for neurological disorders, to its Scientific Advisory Board

SAB now composed of four world-leading immunology experts, including Prof. Zelig Eshhar, who recently received the Novartis Prize for Clinical Immunology

Valbonne, France, August 24, 2016 – TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces the appointment to its Scientific Advisory Board (SAB) of Olivier Danos, PhD, Senior Vice President of Cell and Gene Therapy at Biogen and a world-leading expert in the field of Gene Therapy for hematological and neurological diseases.

"Dr. Olivier Danos has pioneered technologies of central importance in the field of gene therapy and genome editing," said Arnaud Foussat, Chief Scientific Officer of TxCell. "He is another significant addition to our SAB, which already includes leading experts in immunology, T-cell biology and chimeric antigen receptors. These include Professor Zelig Eshhar as Chairman, who was recently awarded the prestigious Novartis Prize for Clinical Immunology. We are looking forward to their insights and advice on our current and future R&D programs targeting severe chronic autoimmune and inflammatory diseases."

Dr. Danos has led Biogen's gene therapy research group, a team dedicated to identifying and developing new technologies for gene transfer and genome engineering, since 2014. Prior to Biogen, Dr. Danos served as Senior Vice President, Molecular Medicine, Synthetic Biology and Gene Regulation, at Kadmon Pharmaceuticals, from 2011 to 2014. In this role, he was instrumental in assembling a gene therapy program and a technology platform for the development of controllable gene expression systems. Prior to Kadmon, Dr. Danos was the Director of the Gene Therapy Consortium at University College, London, and led a gene therapy research team at the Necker Hospital - Enfants Malades in Paris. His other previous appointments include Scientific Director of Généthon and Senior Research Director with the CNRS in France.

TxCell created its SAB in March 2016 with the appointment of the first three members: Professor Zelig Eshhar (*Chairman*), Professor of Immunology, Chair of Immunology Research, Weizmann Institute of Science, Rehovot, Israel; Professor Chiara Bonini, Head of Unit, Experimental Hematology, San Raffaele Hopital, Milan, Italy; and Doctor Bernard Malissen, Research Director, Immunology, Center of Marseille-Luminy, Marseille, France.

Professor Zelig Eshhar awarded the Novartis Prize for Clinical Immunology

On August 22, 2016, Professor Eshhar received the Novartis Prize for Clinical Immunology at the 16th International Congress of Immunology (ICI) in Melbourne, Australia. The prize was awarded to three scientists, including Professor Eshhar, for their work on cellular immunotherapy using Chimeric Antigen Receptor-T cells (CAR-T-cells) for diseases such as cancer. The winners were selected by an independent jury of seven world-class immunologists for their groundbreaking research into the biology of the immune system.

Professor Eshhar pioneered the CAR approach and was the first scientist to demonstrate the therapeutic potential of CAR-Treg cells in preclinical models of intestinal inflammation. In June 2016, TxCell obtained exclusive worldwide rights to a patent co-invented by Professor Eshhar which covers all redirected, genetically engineered T regulatory cells (CAR-Tregs) and their use in the suppression of autoimmune and inflammatory diseases. This patent has already been granted in Europe and is under review in the United States.

About TxCell – www.txcell.com

TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical-stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated.

TxCell is developing two proprietary technology platforms, ASTrIA and ENTrIA. ASTrIA is composed of autologous antigen-specific Type 1 Tregs. Ovasave®, TxCell's lead drug-candidate originating from the ASTrIA platform, is currently in a phase IIb clinical trial in refractory Crohn's disease patients. ENTrIA is composed of Chimeric Antigen Receptor engineered FoxP3+ regulatory T cells (CAR-Treg). In this area, TxCell is pursuing two CAR-Treg development programs in collaboration with leading European research institutions: one targeting Lupus Nephritis with Ospedale San Raffaele in Milan and the other targeting Bullous Pemphigoid with the Lübeck Institute of Experimental Dermatology.

Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.

Contacts

TxCell
Caroline Courme
IR & Communication Director
Tel: +33(0) 4 97 21 83 00
caroline.courme@txcell.com

Image Box – Press relations
Neil Hunter / Michelle Boxall
Tel: +44(0) 20 8943 4685
neil.hunter@imageboxpr.co.uk
michelle.boxall@imageboxpr.co.uk

NewCap – Investor relations
Julien Perez / Pierre Laurent
Tel: +33 (0)1 44 71 98 52
txcell@newcap.eu

Disclaimer – TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered *per se* as historical facts, including TxCell's ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking

statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company's products, which may not succeed, or in the delivery of TxCell's products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 "Risk factors" of the 2015 *document de référence* approved by the AMF on May 24, 2016 under number R.16-048. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be "accurate, precise and fairly presented"), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.